AVROBIO is a clinical-stage gene therapy company focused on developing potentially curative ex vivo lentiviral gene therapies to treat patients with rare diseases following a single dose treatment regimen. Co.'s gene therapies employ hematopoietic stem cells (HSC) that are harvested from the patient and then modified with a lentiviral vector to insert the functional copy of the gene that is mutated in the target disease. Co. has four HSC gene therapy programs: VR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II; and AVR-RD-03 for the treatment of Pompe disease. The AVRO average annual return since 2018 is shown above.
The Average Annual Return on the AVRO average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AVRO average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AVRO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|